A Bitcoin power-law model created in 2013 extends the asset's early price trend using days since its 2009 genesis block, fitting historical data well but excluding key market factors like adoption, regulation, and inflation. The model's formula is a statistical trendline rather than a valuation tool, and it remains part of Bitcoin analysis despite not adjusting for later market changes. Current Bitcoin price and volume data provide context but do not alter the model's assumptions. This model helps understand Bitcoin's growth pattern but should be used alongside other market indicators.
The Bitcoin power-law model and its long-term price trend offer context for cryptocurrency market dynamics. For readers following major cryptocurrencies, here is Pluang's market snapshot as of Oct 14, 2026 05:41 WIB: out of 50 major cryptocurrencies, 26 rose and 23 fell today. Notable movers include AXS at Rp20.440 with a 1-day change of -4.78% and a typical hold time of 62 days, COMP at Rp405.973 down 4.04% with an 80% buy order activity, and SUSHI at Rp4.297 up 3.66% with a 56% buy order activity.
ZenaTech announced a 27.1% organic revenue growth in its Drone as a Service (DaaS) operations in 2026, driven by integrating AI and drones into surveying and inspection workflows. The company expects Q3 2026 revenues between C$13.4 million and C$14.8...
Nvidia CEO Jensen Huang has reaffirmed his long-standing forecast that global spending on AI infrastructure will surge to between $3 trillion and $4 trillion by 2030. This projection highlights the massive growth potential in the AI sector, driven by...
Targa Resources Corp. announced a quarterly cash dividend of $1.25 per common share for Q3 2026, payable on November 17, 2026, to shareholders of record as of October 30, 2026. The company will release its Q3 2026 financial results before market open...
Applied Materials projects sustained demand for its chipmaking equipment driven by AI infrastructure growth, expecting faster spending on wafer fab equipment through 2030. The company aims to increase its market share by over 2 percentage points from...
uniQure released 48-month data for its Huntington's disease drug AMT-130 showing a 44% slowing of disease progression, down from 75% at 36 months. This weaker result caused the stock to drop 37.3% in one day. The company had already submitted an FDA ...
